Search

Author/Creator Koyama, Ryo

11. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2019)

Authors:
Nakagawa, Kazuhiko; Garon, Edward B; Seto, Takashi; Nishio, Makoto; Ponce Aix, Santiago; Paz-Ares, Luis; Chiu, Chao-Hua; Park, Keunchil; Novello, Silvia; Nadal, Ernest; Imamura, Fumio; Yoh, Kiyotaka; Shih, Jin-Yuan; Au, Kwok Hung; Moro-Sibilot, Denis; Enatsu, Sotaro; Zimmermann, Annamaria; Frimod...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 12(2019)
Page Start:
1655
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Risk factors for serious adverse events due to cytotoxic chemotherapy for advanced non-small cell lung cancer. (2016)

Authors:
Suina, Kentaro; Shukuya, Takehito; Koyama, Ryo; Asao, Tetsuhiko; Honma, Yuichiro; Kato, Motoyasu; Muraki, Keiko; Shibayama, Rina; Shimada, Naoko; Takahashi, Fumiyuki; Sakuraba, Shoko; Takahashi, Kazuhisa
Journal:
Cancer treatment and research communications
Issue:
Number 9(2016)
Page Start:
106
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗